about
Canadian clinical practice guidelines for acute and chronic rhinosinusitis.Antibiotics for acute maxillary sinusitis in adultsSystemic corticosteroids for acute sinusitisAntibiotics for clinically diagnosed acute rhinosinusitis in adultsAntibiotics for acute maxillary sinusitis in adultsAntibiotics for clinically diagnosed acute rhinosinusitis in adultsSystemic corticosteroids for acute sinusitisAntibiotics for clinically diagnosed acute rhinosinusitis in adultsAntibiotics for clinically diagnosed acute rhinosinusitis in adultsSystemic corticosteroids for acute sinusitisAntibiotics for acute maxillary sinusitisFluoroquinolones compared with beta-lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trialsEffectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trialsComprehensive review on endonasal endoscopic sinus surgeryEffectiveness of antibiotics for acute sinusitis in real-life medical practiceLactoferrin and eosinophilic cationic protein in nasal secretions of patients with experimental rhinovirus colds, natural colds, and presumed acute community-acquired bacterial sinusitisCanadian guidelines for acute bacterial rhinosinusitis: clinical summary.Comparative effectiveness and safety of cefdinir and amoxicillin-clavulanate in treatment of acute community-acquired bacterial sinusitis. Cefdinir Sinusitis Study Group.Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cellsTwo pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniaePharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.Deprived TLR9 expression in apparently healthy nasal mucosa might trigger polyp-growth in chronic rhinosinusitis patients.Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections.Evaluation of the clinical microbiology profile of moxifloxacin.IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults.The prevalence of bacterial infection in acute rhinosinusitis: a Systematic review and meta-analysis.Integrating fluoroquinolones into the hospital formulary.Clinical practice guideline (update): adult sinusitis.Rhinosinusitis treatment protocol: changing provider habits in primary care.Strategies for diagnosing and treating suspected acute bacterial sinusitis: a cost-effectiveness analysis.Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections.Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines.Combating bacterial resistance in otorhinolaryngology.No evidence for distinguishing bacterial from viral acute rhinosinusitis using symptom duration and purulent rhinorrhea: a systematic review of the evidence base.Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology.Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.Acute sinusitis. When--and when not--to prescribe antibiotics.The role of the local microbial ecosystem in respiratory health and disease.Changes in microbiota during experimental human Rhinovirus infectionAntimicrobial resistance in respiratory tract pathogens.
P2860
Q21245393-A0EDF6B5-54D0-4902-8671-62F7AACD1B26Q24186686-7FA2C91B-5C8E-4DD3-881F-22A65F2CB179Q24197876-85AEA32B-926B-40E5-872F-F66A28164AEAQ24198144-9F49444E-DA09-4055-9B5D-A8D9A19EC45DQ24200440-3DB597E6-6FF3-45B1-9A6D-738189818963Q24201191-E1BC7ED4-2E4A-4965-BA3D-CB707CC2C064Q24234010-BCE04957-02D7-4BB1-A0F7-AD29AE3EAAA3Q24236631-B2C904F4-6921-4A53-9597-A87A6CD5805BQ24240132-455F772C-F26C-4FF2-8D39-4C673C58D3ADQ24241623-4353CF36-DFCB-42CB-8034-0961F5099030Q24242923-EECF3154-CA4C-4A45-8F64-CAA85563AD77Q24653970-AF11D966-C06B-4620-B953-4CC8794E3956Q24657558-C6B508A0-9567-49C2-82C0-BA30B16E3E61Q26771861-3B9266D4-7269-45A1-ADB4-40BDDEAA3FBAQ28749007-62D9E640-C74C-455B-AADF-D73E185E2FC8Q30305911-76F3F60A-8F35-4BAD-8A5F-9181A1057A25Q30414121-C48A9850-34C0-4B23-B6F8-998FCF0EDAEBQ30452909-7C54A5F3-9035-4A3D-936D-26990EE0D828Q33699965-36B3E25B-DACD-42E3-AC93-D8B29061CC4EQ33975832-3883BB95-3874-443B-B1A5-885B45095692Q33976517-49F2B145-3746-485A-9E94-47F810FDE944Q34061934-EA1D8C55-4DDE-447D-93E0-6523DC8C69C0Q34141064-1C184017-D7DD-45FC-A8B0-E60FFF0CA40FQ34183540-9781429C-EBF1-41FC-85B7-D5009447D31BQ34262840-BFEDCE6C-62A0-4A0D-AB1F-4EBD6DF39813Q34315917-C576298F-7C1F-43B8-8DDF-199765B73F55Q34408454-105994CA-1463-4918-8386-6F97CF64C800Q34469863-27A8C899-4435-432E-8A57-95532710D8CCQ34711355-8CC0C2A4-A41B-4118-A894-75A52961889FQ34744355-1397A5D8-BA12-4235-8DE0-8EA9D479CE7AQ34789110-00E34629-A7E4-4F29-B155-511E3455C25EQ34887935-EE84B5ED-B013-48D3-ADE6-32113AFD426BQ35020653-DDAC9C4A-1519-452F-A3BC-FD1AB3168D0EQ35091124-EC0CE813-64E8-4E22-94C6-3B996A947077Q35213108-F3D587E4-7B53-4025-A361-1CC0E3BAC03CQ35627730-D831A4D6-52C9-4E5C-8FB8-725F72DB3D67Q35645446-C9C2512F-9366-4200-A7BA-A9EEF38C132DQ35684946-1145B602-0E78-4C61-88EF-D6E8DEA45C4AQ35745421-0C4FCB0A-10AB-4F0F-8707-7E5F01A31C22Q35917507-B3915036-1648-48CB-A851-82D59A832D4E
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Acute community-acquired sinusitis.
@ast
Acute community-acquired sinusitis.
@en
type
label
Acute community-acquired sinusitis.
@ast
Acute community-acquired sinusitis.
@en
prefLabel
Acute community-acquired sinusitis.
@ast
Acute community-acquired sinusitis.
@en
P356
P1476
Acute community-acquired sinusitis.
@en
P2093
Gwaltney JM Jr
P304
1209-23; quiz 1224-5
P356
10.1093/CLINIDS/23.6.1209
P407
P577
1996-12-01T00:00:00Z